Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392
Rangering i aksjer
#3600
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical... Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.
Aksjekurs
$3.75
Markedsverdi
$4.75B
Endring (1 dag)
1.13%
Endring (1 år)
-51.71%
Land
CN
Handel Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Kategori
Healthcare
P/S-forhold for Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
P/S-forhold per October 2026 TTM: 15.67
Ifølge Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 15.67. Ved slutten av 2023 hadde selskapet et P/S-forhold på 17.18.
P/S-historikk for Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. fra 2013 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 15.67 | -62.38% |
| 2024 | 41.67 | 142.53% |
| 2023 | 17.18 | 69.95% |
| 2022 | 10.11 | -48.04% |
| 2021 | 19.46 | -35.13% |
| 2020 | 29.99 | 775.33% |
| 2019 | 3.43 | -14.52% |
| 2018 | 4.01 | 1.37% |
| 2017 | 3.95 | -11.91% |
| 2016 | 4.49 | -19.44% |
| 2015 | 5.57 | -11.75% |
| 2014 | 6.31 | -13.45% |
| 2013 | 7.30 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | -36.06% |
US
|
|
| 40.55 | 158.70% |
US
|
|
| 3.96 | -74.73% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -35.27% |
NL
|
